The Institute for Applied Biomedicine is developing drugs to treat immune system diseases. We are a not-for-profit biotechnology firm committed to making our drugs accessible to all.
Please follow the links below to learn more about the Institute's new AIDS drug, Immudel-gp120. The information in the first three sections was written to be accessible to people with a variety of scientific backgrounds.
- Direct Infection Model - initial research indicated that the primary cause of immune system failure was direct infection of T4 cells by HIV. This section summarizes the direct infection model and why increasing numbers of researchers are questioning it.
- Autoimmune Model - this model proposes that T4 cell failure and death are primarily caused by an autoimmune attack against the T4 cells, triggered by the presence of HIV. This section summarizes the autoimmune model and relevant research.
- Details of Immudel-gp120 - detailed description of the design of the Institute's AIDS drug, how it would work, proposed dosing, and possible side effects.
- Pilot Test Results - results of in vitro and in vivo tests for safety and efficacy of Immudel-gp120.
- Expert Review - the responses of experts to the autoimmune model and the design of Immudel-gp120.
- Literature Excerpts - excerpts from some of the scientific papers on which the autoimmune model and drug design are based.
- Medical Hypotheses Article - A scientific article by the Institute detailing the autoimmune model of AIDS and the design of Immudel-gp120, published in the peer-reviewed journal, Medical Hypotheses (Feb. 1999, vol. 52, no. 2, pp. 133-146).
- References - a complete list of the scientific literature references used in the above article; additional references used on this site.
© 1997-2008 Institute for Applied Biomedicine. All Rights Reserved. Legal Notices.